Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 145 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Eflornithine in combination with Sulindac for Familial Adenomatus Polyposis	Eflornithine (CPP-1X; Difluoromethylornithine; DFMO; Vaniqa; eflornithine hydrochloride monohydrate) , Sulindac	Familial adenomatous polyposis (FAP)	Gastroenterology , Genetic Disorders	2018	View \| Download
Edaravone for amyotrophic lateral sclerosis	Edaravone (IV) (Radicava; MCI-186; Radicut; Edaravone)	Motor neurone disease (MND or ALS)	Neurology	2018	View \| Download
Durvalumab in combination with Tremelimumab for recurrent or metastatic squamous cell carcinoma of the head and neck – first line	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206)	Head and neck cancer	Head and Neck Cancer	2018	View \| Download
Durvalumab in combination with Tremelimumab and Standard of Care Chemotherapy for EGFR Negative, ALK Negative Metastatic NSCLC– First Line	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2018	View \| Download
Dupilumab for Children Aged 12 Years to 17 Years with Moderate to Severe Atopic Dermatitis	Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893)	Atopic dermatitis	Dermatology	2018	View \| Download
Depatuxizumab mafodotin for newly diagnosed EGFR‐amplified glioblastoma – first line	Depatuxizumab mafodotin (ABT-414) , Temozolomide (Temodar; Temodal; SCH 52365)	Glioma	Neurological Cancer	2018	View \| Download
Darolutamide for Non‐metastatic, Castration-resistant Prostate Cancer	Darolutamide (ODM-201; BAY-1841788; Nubeqa)	Prostate cancer	Male Reproductive Cancer	2018	View \| Download
Daratumumab in combination with Bortezomib, Melphalan and Prednisone for Multiple Myeloma – first line	Bortezomib (Velcade; bortezomib mannitol boronic ester) , Daratumumab (Darzalex; JNJ-54767414) , Melphalan , Prednisone (Decadron; Lodotra)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2018	View \| Download
Daratumumab in addition to Bortezomib, Thalidomide and Dexamethasone for newly diagnosed Multiple Myeloma	Bortezomib (Velcade; bortezomib mannitol boronic ester) , Daratumumab (Darzalex; JNJ-54767414) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Thalidomide (Taldo)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2018	View \| Download
Cysteamine bitartrate for cystic fibrosis exacerbations	Cysteamine bitartrate (Procysbi; RP103; Lynovex; NM001; Cystadrops; Mercaptamine)	Cystic fibrosis	Genetic Disorders , Respiratory System	2018	View \| Download